Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.2.1.15 (
pectinase
)
2,440
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The interaction between fungal endopolygalacturonases (EPGs) and
polygalacturonase
-inhibiting proteins (PGIPs) found in plant cell walls has been well established. The typical
EPG
/PGIP interaction is characterized by high affinity, reversibility, and a 1:1 stoichiometry that results in lowering the catalytic rate of a particular
endopolygalacturonase
by up to 99.7%. Various
EPG
and PGIP isoforms and glycoforms have been isolated and characterized, and combinations of EPGs and PGIPs demonstrate a range of enzyme inhibition.
EPG
/PGIP interactions have prompted many researchers to suspect the involvement of these proteins in the production of specific signals (oligosaccharins) during plant pathogenesis. We have recently reported on initial studies in our laboratory indicating that, for certain
EPG
/PGIP combinations, the specific activity of
EPG
is increased beyond that characteristic of the enzyme alone. In this paper, we present a detailed analysis of the product of the interaction of native Phaseolus vulgaris PGIP-2 with five EPGs from Aspergillus niger, namely PGI, PGII, PGA, PGB, and
PGC
in the presence of homogalacturonan. We demonstrate that for PGA and
PGC
, the interaction with PGIP-2 may result in either inhibition or activation in a manner that is pH dependent. This data suggests the need for a reevaluation of the conventional description applied to PGIPs; suggestions include
polygalacturonase
-binding protein and
polygalacturonase
-modulating protein.
...
PMID:Polygalacturonase-inhibiting proteins can function as activators of polygalacturonase. 1530 10